Corcept submits mifepristone MAA

Corcept Therapeutics Inc. (NASDAQ:CORT) disclosed in its 3Q13 financial results that it submitted an MAA to EMA for Corluxin mifepristone to treat endogenous Cushing's syndrome. Corcept already markets the progesterone and cortisol receptor antagonist as Korlym in the U.S. to treat hyperglycemia secondary to endogenous Cushing's syndrome in adults with Type II diabetes or glucose intolerance. Cushing's syndrome is a hormone disorder caused by high levels of cortisol in the blood. Corcept reported $2.6 million in net revenue for the quarter, up 136% from 3Q12 but missing the Street's $3.3 million estimate. The company said it expects 2013 revenues of $9.6 million. ...